Вы находитесь на странице: 1из 17

:

.
..., . .. 1, ..., . .. 2, ... .. 3
1

-
" (. . .. ) , 2
(. . .. ), 3
-,

2013.- 4.-.94-102
________________________________________________________________________________
___________________


: , ,

_________________________________________________________________________

(),
.
800 . , 38 . [1].
2009 . 211 731 , 40 676
[2]. 10
, -,
. ,
2-
,
,
() [1,3-5].

(, /
, , ,
.), , ,
,

.
, ,
( 30 ) , ( 12 )
( 55 ).

[6],
.


,
.
2001 . , 25-
(1975-2000 .): 45
(), 20-
[8].
82 % 80 % , 13 % 10
% 5 % 10 % ,
[7]. ,
, ,
(Womens Health Initiative
(WHI), [8,9]. 2002 . ,
, , , -
. 2003 .
(Million Women
Study (MWS) [10]. 2003 .
EMA (European Medicines Agency) MHRA (Medicines and Healthcare products
Regulatory Agency), T

, ,
.

WHI MWS ,
, , ,
.
MWS WHI, , , ,
,

[11,12].
,
. Menopause Matters, (www.menopausematters.co.uk) , 70%
, 2 000- , 50 , ..
, 45% ,
, [13].

, [14,15].

2000-

. WHI , ,
,
. ,
, ,
,
(,
).

,
. ,
,
[16] ,
.

, WHI
, ,
.

,
.
,
.

,
.

1995 . (Nurses' Health Study (NHS),


1976 1992 . (n = 121 700),
( > 10 )
[17]. 1997 .
(Collaborative Group of
Hormonal Factors in Breast Cancer) -
51 (n= 52 705, n= 108 411,
) [18] , > 5
() 1,3 ( ,
), > 15 1,6. 5
,
.
NHS (n = 11 508),
,

, , 15 ( = 1,18 (95% 0,951,48) 20 ( =1,42


(95% 1,131,77) [19]. NHS , ,
20 ,
,
, , - --
.

MWS [10]
.
, ,
( = 2,00, 95% 1,912,09),
( = 1,30, 95% 1,221,38).
,
,
[20],
,
, .

HERS (Heart and


Estrogen/Progestin Replacement Stud) 1 380 ,
( () 0,625
() 2,5) 1383 , ,

7 [21]. WHI
(),

[22]. WHI 1991 .

. WHI :
(), (+
) .
() ,
.

WHI,
(n = 10 739 : 0,625
, 7 ( = 0,77
(95% 0,59-1,01) [23]. 6 10 000
/ , (P = 0,06). ,
Stefanick .

( = 0,71 (95% 0,52-0,99) [24]


.

0,27% 0,35%
( =
0.77; 95% 0,62-0,95) , 11,8
[25]. ,
(6 , 0.009% ) (16 ,
0.024% ; = 0.37; 95% 0,13-0,91; P = 0.03).
, ,
(P = 0,04) [25].

WHI
, ,
. , 1970- .

[26].
Craig- Jordan . , ,
, ,
[27]. ,
,
, (gap time),
[28].
?
,
, [29]. ,
( ),
[30]. , ,
,
.


,
WHI: 1,26 ( 1.001.59) [8],
1,24 (, 1.011.54) [9]. , ,
,
. , ,
, ( = 1,09, 95% 0,86-1,39), ..
. , ,
, ,
. ,
, . ,
8 506 8 102 , ,

.

> 5 8 10 000
/ . ,
.
, , WHI
( 63 ) (0,625
), ,
.

Shapiro .,
,
WHI ,
[31]. ,
< 0,1 % , < 1,0
1000 [32].
,
, , ,
[32]. ,
,
, .


,
(Selective Tissue Estrogenic Activity Regulator (STEAR) [33]
. MWS
( = 1,45; 95% 1,251,67) [10],
(LIFT study) ( = 0.32; 95%
0,130,80) [34]. :
(60-85 ) ,
WHI , T-
[35]. (3 ),
, (6
19 ), (
). EMAS
[36]. ,
1,25 . ,
(LIBERATE),
,
[37]. , , ,

, ,
.


- [32,38].

WHI

10 WHI,
, :
, ( ,
, ).

WHI, 2002 .
( ) 2004 . (-) ,
, ,
. 2012 .
,
( ) , , 11,7
[39,40]. , - Chlebowski
[http://healthland.time.com/2012/03/07/estrogen-after-menopauselowers-breast-cancer-risk-forsome-women/#ixzz1oW5hS3Gd]:
, ,
. , ,
. ,
, .
WHI ,
[40].
, , ,

, ,
,
, WHI. ,
,
, , ,
4
, .

,
, -, .

,
(Danish Osteoporosis Prevention Study), 16 ,
- [41].
1 006 4558 ( 50
) ( , 7 ) ,

: (n=502)
( + )
(, n=504).
, , .
,
-
(36 v 39 , = 0.92; 95%
0,58-1,45; P=0,71), (10 17
, = 0.58; 95% 0,27-1,27; P=0,17).

- Kronos Early Estrogen Prevention Study (KEEPS)

-,
-

( )
. KEEPS 727 42-58
( 52,7 ), 3 ( 1,43),
0,45 / ( ,
0,625/ WHI) ( ) 50
/ + 12
, [42].
, ,
, ,
, , ,
,
.

WHI +
,

. 2002 .
( = 0.9; 95% 0,65-1,5)
(n=3 175),
, , 8,9 , 83%
, , ,
[43]. ,
(E3N cohort study) (n= 59 216,
8 ),
+ (= 1.08; 95% 0,89-1,31),
+ ( = 1.18; 95% 0,95-1.48) ( =
1.69; 95% 1,50-1,91).
5 ( = 1.13; 95% 0,49-2,22),
[45].
EPIC (n=133 744,
8,6) . ,
, [46]. EPIC
4 312 ,

. ,
,
.
, ,

[46].

Endocrine Society (, , )
, 5
[47],
.

, , ,
, [48].
in vivo
:
,
[49,50].
,
. ,
, [51].

,
,

, , .
(),
()
.
,
, , , ,

,
,
,

,
[52,53].


.
, -,
.
,

, WHI [54 ]. ,
, +
, -, ,
, - [55 ]. ,
, ,
, ,

.


EURAS-HRT, 7
30 000 (> 100 000 -
),

WHI, [56].

/
( = 0,7; 95% 0,5-1,2).
,
. ,
,
, .
( )
, /
[4,57].


, . , 7%
50 80 (
, 6% in situ 1% ).
. ,
10 ,
[58]. WHI
199 (n=8 102)
150 (n=8 506), ..
0.49 %.


:
WHI 7 %
, ,
(0.49 % 7 %) ,
[47].
, -
,
.

, 10
.
,
. ,
(International Menopause Society (IMS) 2012 .

[59].
: 50 ,
, . ,

. , ,
. ,
IMS [32].
, ,

(
, )
[32].


CLIMACTERIC N. Panay A. Fenton
[60] . ,
, ,
. ,
WHI .

,

, .
,

.
:
,
. --
, ,
, .

(American Cancer Society)


, 89%
20092010 . 5 ,
82% 10 .
, ,
.
.

, , WHI
, ,

. , ,
WHI,
.
,
.
,
,
.

, ,
.
, .
,
, .
,
, ,
,
WHI.
.

1.

, .
. 2009;10(2):76-83

2.

U.S. Cancer Statistics Working Group. United States Cancer Statistics: 19992009
Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human
Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2013.
Available at: http://www.cdc.gov/uscs.

3.

.., ..
:
. 2011; 2:53-56.

4.
5.

Gompel , Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI.
Climacteric 2012;15:241-49

6.

Shapiro S, Farmer RD, Stevenson JC, et al. Does hormone replacement therapy (HRT) cause
breast cancer? An application of causal principles to three studies: Part 5. Trends in breast
cancer incidence in relation to the use of HRT. J Fam Plann Reprod Health Care 2013;39:
39:80-88

7.

Trichopoulos D Adami H-O, Ekbom A, et al. Early life events and conditions and breast
cancer risk: from epidemiology to etiology. In J Cancer 2008;122:481485

8.

Bush TL, Whiteman M, Flaws JA et al. Hormone replacement therapy and breast cancer: a
qualitative review. Obstet Gynecol 2001;98:498-508

9.

Rossouw JE, Anderson GL, Prentice RL, et al . Risks and benefits of estrogen plus progestin
in healthy postmenopausal women. JAMA 2002;288:321-333.

10. Chlebowski RT, Hendrix SL, Langer RD, et al. for the WHI Investigators. Influence of
estrogen plus progestin on breast cancer and mammography in healthy postmenopausal
women: the Womens Health Initiative randomized trial. JAMA 2003;289:3243-53
11. Beral V, Banks E, Reeves G, Bull D, for the MillionWomen Study Collaborators. Breast
cancer and hormone-replacement therapy in the Million Women Study. Lancet
2003;362:419427
12. Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy
between 2002 and 2009. Menopause 2012;19 (6):610-615.
13. Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone
therapy prescribing in the United States: long-term effects of the Womens Health Initiative.
Menopause 2012;19 (6):616-621
14. Cumming GP, Currie HD, Panay N, Moncur R, Lee AJ. Stopping hormone replacement
therapy: were women ill advised? Menopause Int 2011;17:82-7
15. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of
estrogen plus progestin. JAMA 2005;294:183-93
16. Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation
of hormone therapy: results from a prospective study in a large health management
organization. Menopause 2011;18(11):1172-7
17. Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone
therapy prescribing in the United States: long-term effects of the Womens Health Initiative.
Menopause 2012;19 (6):616-621
18. Colditz GA, Stampfer MJ, Willett WC, et al. The use of estrogens and progestins and the
risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-9
19. Collaborative Group on Hormonal factors in Breast Cancer. Breast cancer and hormone
replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of
52 705 women with breast cancer and 108 411 women without breast cancer. Lancet
1997;350:1047-1059
20. Chen YC, Colditz GA, Rosner B et al. Unopposed estrogen therapy and the risk of invasive
breast cancer. Arch Intern Med 2006;166:10271032

21. Shapiro S, Farmer RD, Stevenson JC, et al. Does hormone replacement therapy cause breast
cancer? An application of causal principles to three studies Part 4: The Million Women Study.
J Fam Plann Reprod Health Care 2012;38:102109.
22. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular Disease Outcomes During
6.8 Years of Hormone Therapy Heart and Estrogen/Progestin Replacement Study Follow_up
(HERS II) for the HERS Research Group. JAMA 2002;288:58-64
23. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for
perimenopausal and postmenopausal women. Cochrane Database Syst Rev
2012;7:CD004143
24. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in
postmenopausal women with hysterectomy: the Womens Health Initiative randomized
controlled trial. JAMA 2004;291:1701-1712
25. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on
breast cancer and mammography screening in postmenopausal women with hysterectomy.
JAMA 2006;295:1647-657
26.

Anderson R G, Chlebowski RT Aragaki AK et al. Conjugated equine oestrogen and breast


cancer incidence and mortality in postmenopausal women with hysterectomy: extended
follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol
2012;13(5):476-486

27. Bluming A Z, Tavris C. Chains of evidence, mosaics of data: does estrogen cause breast
cancer? How would we know? Chains of evidence, mosaics of data: does estrogen cause
breast cancer? How would we know? Climacteric 2012;15:531537
28. Craig-Jordan V, Lewis-Wambi J, Kim H, et al . Exploiting the apoptotic actions of oestrogen
to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.
Breast 2007;16(Suppl 2):105-13
29. Obiorah I, Jordan VC. Scientific rationale for postmenopause delay in the use of conjugated
equine estrogens among postmenopausal women that causes reduction in breast cancer
incidence and mortality. Menopause 2013;20(4):372-382
30. Preston-Martin S, Pike MC, Ross RK, Henderson BE. Epidemiologic evidence for the
increased cell proliferation model of carcinogenesis. Environ Health Perspect 1993;101(Suppl
5):137-138
31. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med
2006;354:270-282
32. Shapiro S, Farmer RDT, Mueck AO, Seaman H, Stevenson JC. Does hormone therapy cause
breast cancer? An application of causal principles to three studies. Part 3. The Womens
Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37:16572
33. de Villiers T J, Pines A , Panay N. et al, on behalf of the International Menopause Society.
Updated 2013 International Menopause Society recommendations on menopausal hormone
therapy and preventive strategies for midlife health/
Climacteric 2013;16:316337

34. Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: Clinical


recommendations and practical guidelines. A report of the International Tibolone Consensus
Group. Maturitas 2005;51:21-28
35. Cummings SR, et al. The effects of Tibolone in older postmenopausal women. N Engl J
Med 2008;359:697708
36. Chen Z, Arendell L, Aickin M, et al. Hip bone density predicts breast cancer risk
independently of Gail score: results from the Womens Health Initiative. Cancer.
2008;113:907-15
37. Gompel A, Rozenberg S, Barlow DH, the EMAS board member. The EMAS 2008 update
on clinical recommendations on postmenopausal hormone replacement therapy Maturitas
2008;61:227232
38. Kenemans P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor
symptoms: a double-blind, randomised, noninferiority trial. Lancet Oncology
2009;10(2):135146
39. The North American Menopause Society. The 2012 Hormone Therapy Position Statement of
The North American Menopause Society. Menopause 2012;19:257
40. Anderson GL , Chlebowski RT, Aragaki AK , et al . Conjugated equine oestrogen and breast
cancer incidence and mortality in postmenopausal women with hysterectomy: extended
follow-up of the Womens Health Initiative randomised placebo-controlled trial. Lancet
Oncol 201 ;13:476-86.
41.

Chlebowski R T , Anderson G . C hanging concepts: menopausal hormone therapy and


breast cancer. J Natl Cancer Inst 2012;104:517-27.

42. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on
cardiovascular events in recently postmenopausal women: Randomised trial. BMJ 2012;
DOI: 10.1136/bmj.e6409
43. Kronos Longevity Research Institute. Hormone therapy has many favorable effects in newly
menopausal women: Initial findings of the Kronos Early Estrogen Prevention Study
(KEEPS). Press release dated 3 October 2012. http://www.menopause.org /docs/agm/generalrelease.pdf?sfvrsn=0[accessed 2 February 2013].
44. de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy
and risk of breast cancer in a French cohort study of 3 175 women. Climacteric 2002;5:332:
332-340
45. Fournier A, Berrino F, Clavel-Chapelon F.et al. Unequal risks for breast cancer associated
with different hormone replacement therapies: results from the E3N cohort study. Breast
Cancer Res Treat 2008;107:307308
46. Lyytinen
H,
Pukkala
E,
Ylikorkala
O.
Breast
cancer
risk
in
postmenopausalwomenusingestradiol-progestogentherapy. Obstet Gynecol 2009;113:6573
47. Bakken K, Fournier As, Lund E, et al. Menopausal hormone therapy and breast cancer risk:
impact of different treatments. The European Prospective Investigation into Cancer and
Nutrition Int J Cancer 2011;128:144-56

48. Santen RJ, Allred DC, Ardoin CA, et al. Postmenopausal Hormone Therapy. An Endocrine
Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism 2010; 95
(Suppl. 1): 1-66
49. Santen RJ Risk of breast cancer with progestins: critical assessment of current data.
Steroids 2003;68:953964
50. Ross RK, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen
versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328332
51.

Horwitz KB, et al. Rare steroid receptor-negative basal-like tumorigenic cells in luminal
subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008;105:57745779

52. Wiebe JP, et al. The 4-pregnene and 5-pregnane progesterone metabolites formed in
nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and
adhesion. Cancer Res 2000;60: 936943
53. Bray JD, Jelinsky S, Ghatge R, et al. Quantitative analysis of gene regulation by seven
clinically relevant progestins suggests a highly similar mechanism of action through
progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol
2005;97:32841
54. Fu XD, Giretti MS, Goglia L, et al. Comparative actions of progesterone,
medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and
invasion. BMC Cancer 2008;8:166
55. Otto C., Fuchs I, Altmann H.et al. Comparative analysis of the uterine and mammary gland
effects of drospirenone and medroxyprogesterone acetate. Endocrinology 2008;149(8):395259
56. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or
estrogen plus medroxyprogesterone acetate is associated with increased epithelial
proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559
4565
57. Heinemann K, Assmann A, Dinger J. The Safety of Oral Hormone Replacement Therapy:
Final Results from the EURAS-HRT Study. Pharmacoepidemiology & Drug Safety 2012; 21
(Suppl. 3):365.
58. Pichad C, Plu-Bureau G, Neves-e Castro M, Gompel A. Insulin resistance, obesity and
breast cancer risk. Maturitas 2008;60:10-18
59. Dietel M, Lewis MA, Shapiro S.et al. Hormone replacement therapy: pathobiological
aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a
mini-review. Hum Reprod 2005 20:20522060
60. de Villiers T J, Gass M LS, Haines C J, et al. Global Consensus Statement on Menopausal
Hormone Therapy. Climacteric 2013;16:203204
61. Panay N, Fenton A. Editorial. A global consensus statement on menopause hormone therapy
aims, aspirations and action points. Climacteric 2013;16:201202